Insulet (NASDAQ:PODD) Price Target Raised to $170.00

Insulet (NASDAQ:PODD) had its price target increased by equities researchers at Citigroup from $150.00 to $170.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup‘s price target would indicate a potential upside of 8.91% from the stock’s current price.

Several other brokerages have also recently commented on PODD. Stifel Nicolaus decreased their price target on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and cut their price objective for the company from $210.00 to $153.00 in a research report on Wednesday, August 5th. Leerink Partners lifted their target price on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a report on Thursday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Finally, Canaccord Genuity Group dropped their price target on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $190.80.

Insulet Price Performance

Shares of Insulet stock traded down $8.93 on Thursday, hitting $156.09. 1,319,076 shares of the company traded hands, compared to its average volume of 1,397,986. The stock has a market capitalization of $10.82 billion, a P/E ratio of 29.18, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The business has a 50-day simple moving average of $141.65 and a 200 day simple moving average of $178.00.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same quarter in the prior year, the business earned $1.24 earnings per share. Insulet’s revenue for the quarter was up 19.2% on a year-over-year basis. Research analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insulet

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Insulet during the 2nd quarter valued at about $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares during the last quarter. Man Group plc bought a new position in shares of Insulet in the 2nd quarter valued at about $78,746,000. Amundi grew its position in Insulet by 13.6% in the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after acquiring an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE purchased a new position in Insulet in the second quarter worth about $64,921,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, ahead of the $1.59 consensus, and revenue of $842 million, up 19.2% year over year and above estimates. Read article
• Positive Sentiment: The company announced a $1 billion share-repurchase authorization, which could support shareholder returns. Read article
• Positive Sentiment: Several firms raised their price targets: RBC to $180 and Bernstein to $200, both with outperform ratings; Leerink Partners raised its target to $167 while maintaining market perform. RBC article
• Negative Sentiment: Management expects slower growth in 2027 and anticipates competitors taking some share from its Omnipod product. That outlook may be overshadowing the Q3 beat and prompting caution about future growth. Read article

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.